Quarter | Holdings | Value $ | Bought | Sold | Net | Top Holdings | Form Type | Date Filed |
---|
Quarter | Holdings | Value $ | Bought | Sold | Net | Top Holdings | Form Type | Date Filed |
---|---|---|---|---|---|---|---|---|
Q4 2024 | 188 | $7.57B | +$258M | -$489M | -$231M | AVGO, T, C, CME, PFE | 13F-HR | 2/13/2025, 06:04 PM |
Q3 2024 | 192 | $7.68B | +$1.08B | -$364M | +$720M | AVGO, T, C, CME, PFE | 13F-HR | 11/8/2024, 05:55 PM |
Q2 2024 | 189 | $7.11B | +$517M | -$619M | -$103M | AVGO, T, C, PFE, CME | 13F-HR | 8/7/2024, 06:37 PM |
Q1 2024 | 187 | $7.17B | +$404M | -$966M | -$562M | AVGO, C, T, JPM, CME | 13F-HR | 5/13/2024, 04:58 PM |
Q4 2023 | 196 | $6.93B | +$647M | -$470M | +$178M | AVGO, C, CME, T, JPM | 13F-HR | 2/8/2024, 11:15 AM |
Q3 2023 | 196 | $6.08B | +$492M | -$445M | +$47.7M | AVGO, CME, PFE, JPM, C | 13F-HR | 11/13/2023, 10:38 AM |
Q2 2023 | 184 | $6.17B | +$433M | -$597M | -$165M | AVGO, CME, PFE, JPM, QCOM | 13F-HR | 8/8/2023, 04:04 PM |
Q1 2023 | 185 | $6.05B | +$327M | -$468M | -$141M | AVGO, CME, PFE, JPM, QCOM | 13F-HR | 5/9/2023, 01:01 PM |
Q4 2022 | 201 | $5.91B | +$254M | -$596M | -$341M | PFE, AVGO, CME, JPM, RF | 13F-HR | 2/7/2023, 06:23 PM |
Q3 2022 | 200 | $5.65B | +$410M | -$691M | -$282M | CME, PFE, AVGO, RF, QCOM | 13F-HR | 11/14/2022, 05:59 PM |
Q2 2022 | 201 | $6.53B | +$669M | -$608M | +$60.4M | CME, ABBV, AVGO, PFE, QCOM | 13F-HR | 8/5/2022, 02:04 PM |
Q1 2022 | 196 | $7.63B | +$411M | -$766M | -$355M | CME, AVGO, ABBV, PFE, QCOM | 13F-HR | 5/11/2022, 06:23 PM |
Q4 2021 | 208 | $8.53B | +$803M | -$1.04B | -$239M | AVGO, CME, ABBV, QCOM, PFE | 13F-HR | 2/10/2022, 05:22 PM |
Q3 2021 | 209 | $8.15B | +$707M | -$984M | -$277M | CME, AVGO, ABBV, JPM, HD | 13F-HR | 11/9/2021, 06:23 PM |
Q2 2021 | 1 | $9.01M | $0 | $0 | GTES | New Holdings | 10/12/2021, 04:08 PM | |
Q2 2021 | 206 | $8.7B | +$676M | -$859M | -$183M | CME, JPM, ABBV, AVGO, CIM | 13F-HR | 8/10/2021, 06:55 PM |
Q1 2021 | 207 | $8.62B | +$719M | -$1.09B | -$372M | JPM, CME, ABBV, AVGO, BABA | 13F-HR | 5/14/2021, 03:38 PM |
Q4 2020 | 227 | $8.43B | +$1.71B | -$2.12B | -$408M | CME, JPM, AVGO, ABBV, BABA | 13F-HR | 2/9/2021, 01:51 PM |
Q3 2020 | 164 | $7.56B | +$343M | -$957M | -$614M | BABA, JPM, CME, ABBV, HD | 13F-HR | 11/5/2020, 01:06 PM |
Q2 2020 | 159 | $7.79B | +$800M | -$1.39B | -$587M | ABBV, BABA, JPM, CME, HD | 13F-HR | 8/7/2020, 02:17 PM |
Q1 2020 | 163 | $6.99B | +$697M | -$1.44B | -$747M | BABA, CME, JPM, WBA, RDSA | 13F-HR | 5/13/2020, 01:43 PM |
Q4 2019 | 171 | $10.4B | +$500M | -$1.4B | -$903M | CME, JPM, RDSA, BABA, QCOM | 13F-HR | 2/7/2020, 06:05 PM |
Q3 2019 | 170 | $10.4B | +$576M | -$751M | -$175M | CME, JPM, RDSA, BABA, HD | 13F-HR | 11/12/2019, 01:20 PM |
Q2 2019 | 170 | $10.4B | +$723M | -$1.02B | -$297M | CME, RDSA, JPM, BABA, QCOM | 13F-HR | 8/6/2019, 12:04 PM |
Q1 2019 | 175 | $10.3B | +$640M | -$1.51B | -$868M | RDSA, CME, JPM, BABA, WBA | 13F-HR | 5/7/2019, 04:00 PM |
Q4 2018 | 171 | $10.2B | +$766M | -$901M | -$134M | CME, RDSA, JPM, WBA, QCOM | 13F-HR | 2/6/2019, 04:00 PM |
Q3 2018 | 161 | $12B | +$811M | -$2.29B | -$1.48B | RDSA, CME, JPM, WBA, QCOM | 13F-HR | 11/2/2018, 10:58 AM |
Q2 2018 | 227 | $13.2B | +$1.06B | -$1.47B | -$404M | RDSA, CME, JPM, WBA, HD | 13F-HR | 8/14/2018, 10:38 AM |
Q1 2018 | 231 | $13.3B | +$1.27B | -$2.07B | -$801M | RDSA, CME, JPM, WBA, HD | 13F-HR | 5/7/2018, 10:43 AM |
Q4 2017 | 243 | $14.4B | +$1.22B | -$1.27B | -$51.8M | JPM, CME, RDSA, HD, QCOM | 13F-HR | 2/14/2018, 10:17 AM |
Q3 2017 | 243 | $14B | +$1.91B | -$1.48B | +$427M | JPM, CME, RDSA, HD, MRK | 13F-HR | 11/13/2017, 09:59 AM |
Q2 2017 | 249 | $13.1B | +$1.75B | -$1.47B | +$284M | JPM, CME, RDSA, HD, MRK | 13F-HR | 8/14/2017, 10:22 AM |
Q1 2017 | 265 | $12.3B | +$1.47B | -$2.83B | -$1.35B | JPM, CME, RDSA, HD, WBA | 13F-HR | 5/9/2017, 10:36 AM |
Q4 2016 | 273 | $13B | +$1.39B | -$1.82B | -$431M | JPM, CME, RDSA, HD, WBA | 13F-HR | 2/10/2017, 01:48 PM |
Q3 2016 | 254 | $13.1B | +$1.21B | -$1.69B | -$482M | JPM, CME, RDSA, AGN, HD | 13F-HR | 11/14/2016, 09:27 AM |
Q2 2016 | 260 | $12.9B | +$1.35B | -$3.48B | -$2.13B | JPM, RDSA, CME, AGN, HD | 13F-HR | 8/12/2016, 12:05 PM |
Q1 2016 | 264 | $15B | +$2.12B | -$2.97B | -$853M | JPM, CME, HD, T, C | 13F-HR | 5/12/2016, 10:58 AM |
Q4 2015 | 292 | $15.7B | +$1.61B | -$2.04B | -$432M | CME, JPM, HD, T, RDSA | 13F-HR | 2/9/2016, 11:57 AM |
Q3 2015 | 275 | $15.9B | +$3.2B | -$2.88B | +$320M | CME, JPM, HD, T, AGN | 13F-HR | 11/12/2015, 10:17 AM |
Q2 2015 | 306 | $17.4B | +$3.61B | -$4.5B | -$891M | CME, JPM, RDSA, HD, LBTYK | 13F-HR | 8/12/2015, 09:25 AM |
Q1 2015 | 306 | $18B | +$2.49B | -$4.57B | -$2.08B | JPM, CME, RDSA, NXPI, LBTYK | 13F-HR | 5/13/2015, 11:53 AM |
Q4 2014 | 303 | $20B | +$2.74B | -$5.32B | -$2.58B | JPM, RDSA, LBTYK, BIDU, BABA | 13F-HR | 2/11/2015, 11:04 AM |
Q3 2014 | 312 | $22.2B | +$2.5B | -$4.96B | -$2.46B | JPM, BIDU, B108PS, LBTYK, SLB | 13F-HR | 11/12/2014, 10:07 AM |
Q2 2014 | 319 | $25.1B | +$4.35B | -$5.22B | -$871M | SLB, BIDU, TSM, JPM, ACN | Restatement | 8/11/2014, 02:35 PM |
Q1 2014 | 292 | $25.4B | +$4.29B | -$4.05B | +$243M | SLB, BIDU, YUM, ACN, BBVA | 13F-HR | 5/14/2014, 04:41 PM |
Q4 2013 | 284 | $26.2B | $0 | $0 | BIDU, SLB, YUM, YNDX, LBTYA | 13F-HR | 2/13/2014, 01:57 PM |